Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

CleverTap Recognized by Great Place to Work® Among India’s Great Mid-size Workplaces

CleverTap

CleverTap, the modern, integrated retention cloud, has been recognized by Great Place to Work® India as one of India’s Great Mid-size Workplaces 2022. CleverTap is recognized for creating and sustaining a high-trust, high performance work culture. In its 6th edition this year for India, the list has grown to include the top 75 companies, up from the top 50 until last year. The rigorous methodology to assess workplace culture and identify India's Great Mid-size Workplaces 2022 is considered the gold standard globally. In the Great Place to Work® India study, they have observed that the Great Mid-size Workplaces have gone above and beyond to create and sustain aspirational organizations. Effective leadership is visible in these workplaces that are fostering a culture of fairness and originality, while offering flexibility to their employees in the current hybrid work environment. Organizations that succeed in establishing high-trust, high-performance cultures, and maximizing human potential by bridging experience gaps, will be Great Places to Work For All in the future. “We’re very excited to be recognized by Great Place to Work® India as one of India’s Great Mid-size Workplaces. Even before the pandemic hit, we believed that an empathetic and flexible work culture is the essence of an organization’s growth,” says Sidharth Malik, Chief Executive Officer, CleverTap. “Our employees and their holistic well-being have always been the top priority for us. The recognition by Great Place to Work® India is a testament to our commitment of building a workplace that is inclusive and driven, and one that provides its people an environment to thrive and succeed in everything they do.” “With homes becoming an extension of people's workplaces, this year companies around the world were challenged to put their people at the center of their strategies. But the organizations that invested in their culture and people before the pandemic have overcome these challenges effortlessly. Being recognized as one of India’s Best Workplaces 2022 demonstrates these organizations' commitment to improving their culture and putting their people first, whatever challenges they face,” says Yeshasvini Ramaswamy, CEO, Great Place to Work®, India. As a global authority on workplace culture, Great Place to Work® has been studying employee experience and people practices across organizations for over three decades. Every year, more than 10,000 organizations from over 60 countries partner with Great Place to Work® Institute for assessment, benchmarking, and planning of actions to strengthen their workplace culture. About CleverTap CleverTap is the modern, integrated retention cloud that empowers digital consumer brands to increase customer retention and lifetime value. CleverTap drives contextual individualization with the help of a unified and deep data layer, AI/ML-powered insights, and automation enabling brands to offer hyper-personalized and delightful experiences to their customers. 1,200+ customers in 60+ countries and 10,000+ apps, including Gojek, ShopX, Canon, Mercedes Benz, Electronic Arts, TED, Jio, Premier League, TD Bank, Carousell, Papa John’s, and Tesco, trust CleverTap to achieve their retention and engagement goals, growing their long-term revenue. Backed by leading venture capital firms, including Sequoia, Tiger Global Management, and Accel, the company is headquartered in Mountain View, California, with offices in Mumbai, Singapore, Sofia, São Paulo, Bogota, Amsterdam, Jakarta, and Dubai. For more information, visit clevertap.com or follow on LinkedIn and Twitter. Forward-Looking Statements Some of the statements in this press release may represent CleverTap’s belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could amount in the actual result being absolutely different from the results anticipated by the statements mentioned in the press release. Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or any related damages Contact Details Sony Shetty sony@clevertap.com Company Website https://clevertap.com/

June 24, 2022 03:18 AM Eastern Daylight Time

NextFerm Technologies announces its first commercial delivery of ProteVin™, in the U.S

NextFerm Technologies Ltd.

Company has delivered two tons of raw material to SpaceMilk, a health and wellness brand, expected to launch its ProteVin™ based product during this summer The company marks the achievement of the second strategic milestone (out of five) for 2022. This announcement follows an earlier announcement made this week about initiating ProteVin’s commercial production The Company is expected to continue supplying ProteVin to customers in the coming weeks, and is currently in dialogues with leading food and dietary supplement brands, for the integration of ProteVin™ in their alternative products (Yokneam Illit, June 22, 2022) – NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, fermentation-based, non-GMO protein alternative and other innovative yeast-based nutrients, announced today of the first commercial delivery of ProteVin to a U.S customer. The Company delivered 2 tons out of SpaceMilk’s purchase order obtained in July 2021. SpaceMilk (Former PrimaLife Nutrition), is a US health and wellness brand and the first to launch a vegan protein powder based on ProteVin™. This protein powder will enable consumers to enjoy vegan protein with animal like nutritional value and perfect taste. The ProteVin™ brand name will appear on the product label, as the leading nutritional substance in the product. SpaceMilk is expected to be launched and available for sale to end users during the coming summer months, mostly online. The supply of the remaining of the order, as well as other open orders, shall continue during the coming weeks. The delivery of the first purchase order marks the achievement of the second out of five milestones set by the Company for 2022. This announcement follows an earlier announcement made this week about the initiation of commercial production (first milestone). The Company continues to progress towards the completion of its objectives for 2022, which include: increasing market demands, receiving additional purchase orders for ProteVin™ and increasing commercial production capacity from current scale of tens of tons to a scale of hundreds of tons per year in 2023. Boaz Noy, Chief Executive Officer of NextFerm, said: "We are excited to launch ProteVin, our vegan protein, as planned, and supply it to our first customers, who has expressed confidence in the product by placing purchase orders even before production has started. The alternative protein market, is currently estimated at $20 billion, and is expected to grow to about $290 billion by 2035, at an annual growth rate of above 20%. Today, it is indisputable that it is the main growth engine for the global food industry. This growing trend of consuming vegan foods as part of a balanced diet is becoming ever more popular within the general population that considers these foods to be healthier and more sustainable. "We are proud to be one of the leading innovators in the alternative protein B2B market, by offering the only vegan protein with a neutral flavor and animal like nutritional value that allow it to be incorporated into a variety of foods. We are also making progress in meeting the rest of the milestones for 2022, including: dialogues with food and nutrition brands, who are looking into incorporating ProteVin into their alternative product lines in such fields as dairy substitutes, powder premixes, snacks and more. At the same time, we are preparing to increase production capacity to a scale of hundreds of tons per year, in order to respond to the expected increase in demands." About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE:NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein with animal-like nutritional value (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 3.5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

June 22, 2022 09:50 AM Eastern Daylight Time

SC Johnson and Global Fund Launch Partnership to Eradicate Malaria; Urge World Leaders to Boost Action to End One of the World’s Deadliest Diseases

SC Johnson

SC Johnson has teamed up with the Global Fund to accelerate the elimination of malaria, a deadly yet preventable and treatable disease that claims the life of a child under the age of five every minute. In addition to announcing their partnership, the two organizations are calling on leaders attending the 2022 Commonwealth Heads of Government Meeting (CHOGM) in Kigali to redouble their efforts to help eliminate the disease. Under an agreement signed by Peter Sands, Executive Director of the Global Fund, and Fisk Johnson, Chairman and CEO of SC Johnson, the partnership will leverage SC Johnson’s core competencies in entomology to drive measurable and economically sustainable social impact in the malaria space in Burundi, Democratic Republic of Congo, Kenya, Rwanda, South Sudan, Tanzania, Uganda and Zanzibar. “Malaria claims the lives of hundreds of thousands of children every year, and yet it remains one of the most neglected diseases on the planet,” said Fisk. “We’ve been working for decades on preventative interventions and innovative solutions, such as spatial repellents, to help those most at risk. We know we can’t tackle this insidious disease alone. That’s why we are partnering with the Global Fund and calling on leaders here in Kigali to redouble their efforts to help end malaria once and for all.” For more than 60 years, SC Johnson has studied insects and the diseases they carry at the company’s Center for Insect Science and Family Health, one of the world’s largest privately funded urban entomology centers. SC Johnson has leveraged that knowledge and expertise to help protect families from insect-borne diseases like malaria and dengue. As part of this partnership, SC Johnson will be providing technical knowledge to support country-led efforts to eliminate malaria. “SC Johnson’s strong expertise in entomology can be a key asset in supporting our partners to accelerate progress in the fight against malaria,” said Peter. “This new initiative is a great example of how the private sector can bring innovative solutions and technical expertise to bear on the fight against the world’s deadliest diseases. Ahead of the Global Fund’s Seventh Replenishment, we will continue to count on our private sector partners to invest with us to defeat HIV, TB and malaria, end health inequity and protect humanity from pandemics.” The Global Fund provides 56% of all international financing for malaria programs (39% of total available resources) and has invested more than US$16 billion in malaria control programs to date. In countries where the Global Fund invests, malaria deaths have dropped by 26% between 2002 and 2020. The announcement comes ahead of the Global Fund’s Seventh Replenishment Conference hosted by U.S. President Joe Biden later this year. The Global Fund’s target is to raise at least US$18 billion to fund its next three-year cycle of grants. A successful Replenishment would save 20 million lives, cut the death rate from HIV, tuberculosis and malaria by 64%, and strengthen systems for health to build a healthier, more equitable world. In the fight against malaria, a successful Replenishment would cut malaria deaths by 62%, reduce malaria cases by 66% and eliminate malaria from an additional six countries by 2026. About the Global Fund The Global Fund is a worldwide movement to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest more than US$4 billion a year to fight the deadliest infectious diseases, challenge the injustice which fuels them and strengthen health systems in more than 100 of the hardest hit countries. Since the beginning of the COVID-19 pandemic, we have invested an additional US$4.3 billion to fight the new pandemic and reinforce systems for health. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund has saved 44 million lives. Information on the work of the Global Fund is available at www.theglobalfund.org Follow the Global Fund on Twitter: http://twitter.com/globalfund Join the Global Fund on Facebook: http://www.facebook.com/theglobalfund About SC Johnson Founded in 1886 and headquartered in Racine, Wisconsin USA, SC Johnson believes that a more sustainable, healthier and transparent world that inspires people and creates opportunities isn't just possible – it’s our responsibility. A heritage of innovation and bold, transparent decisions is why our high-quality products and iconic brands – including OFF! ®, Raid ®, Glade ®, Windex ®, Scrubbing Bubbles ®, Ziploc ®, Mrs. Meyer’s Clean Day ®, method ®, Autan ®, Baygon ®, Mr Muscle ®, Duck ®, Lysoform ® and more – are in homes, schools and businesses in virtually every country worldwide. As a global, purpose-led company, we are committed to making the world a better place today and for future generations. That means relentlessly bringing our expertise in science, innovation and partnerships to bear on some of the world's most pressing environmental and health issues like reducing plastic waste and eradicating malaria. Around the world, we use our resources to unlock greater economic and educational opportunities for people and communities where access may be limited, but curiosity and potential are limitless. See how SC Johnson is a Family Company At Work For a Better World by visiting scjohnson.com or joining us on Facebook, Twitter, LinkedIn, Instagram and YouTube. Contact Details SC Johnson Jen Erickson +1 262-598-6726 jericks@scj.com Company Website https://www.scjohnson.com/

June 22, 2022 03:00 AM Eastern Daylight Time

First-of-Its-Kind National Canine Cancer Registry Offers Ray of Hope to Dog Lovers

YourUpdateTV

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop a tumor, and almost 50% of dogs over age 10 will develop cancer. Recently, Dr. Susan Ettinger, “Dr Sue Cancer Vet”, Veterinary Cancer Specialist and Take C.H.A.R.G.E. Scientific Advisory Board Member, and Lisa Conte, Jaguar Health Founder & CEO, conducted a satellite media tour to talk about the first-of-its-kind national canine cancer registry that offers a ray of hope to dog-lovers everywhere. A video accompanying this announcement is available at: https://youtu.be/UaYbeRw7JGY Designed to be interactive and with open access to academia, the Jaguar Health Canine Cancer: Take C.H.A.R.G.E. ( C anine H ealth A nd R e G istry E xchange), co-sponsored by Jaguar Animal Health, TogoRun, and Ivee, is a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index that provides the veterinary community and canine pet owners with important incidence and prevalence data to help guide canine cancer diagnosis and treatment decisions, at no cost. The Registry began with a retrospective review of more than 35,000 anonymous canine patient records uploaded into a secure customized database and more than 830 confirmed cancer diagnoses and is interactive. Protecting dogs from cancer begins with knowing its impact by breed, type, age, gender, and location Powered by animal health software company Ivee (Intelligent Veterinary Enhanced Experience), only information from canine patients that have been diagnosed with cancer is accessed and data is continuously protected. All research and academia related activities are de-identified and anonymized, following all General Data Protection Regulation (GDPR) guidelines, to ensure 100% participant and veterinary information protection. Currently there is no published state-by-state registry in the U.S. documenting canine cancer, while there are multiple regional European registries that exist and serve to inform both the veterinary and human oncology communities. The Registry also includes the first nationwide Gallup survey of pet owners addressing their experience with canine cancer. Canine Cancer Impact on Humans - Dealing with canine cancer has a major impact on dog owners’ well-being, including depression, anxiety, lack of sleep, and missing work or other obligations; for example, 63 percent of respondents reported feeling a lot of stress and 58 percent reported feeling down and depressed a lot during their dog's cancer. And, more than 8 in 10 dog owners favor the creation of a canine cancer registry to better understand the disease and advance treatments The survey found that the incidence – the percent of U.S. dogs newly diagnosed with cancer in 2021 – was approximately five times incidence of newly diagnosed cancer in humans that year, which is startling since researchers have assumed that canine cancer rates mirror human cancer rates. A complementary Index was established based on pet owner responses to this multi-year nationwide Gallup survey assessing pet owner experience with their dog’s cancer diagnosis and treatment. Together the Registry and Index provides the veterinary community with important information to guide canine cancer diagnosis and treatment decisions and support dog owners by improving canine cancer care. The Gallup survey closed on March 30, 2022, with over 3,800 respondents, including over 600 responses from dog owners with canine cancer experience. Canine cancer patient records uploaded to the Registry are updated regularly thanks to ongoing input from participating veterinarians and owners of dogs who have been diagnosed with cancer. If your dog passed away from cancer, you can contribute to building hope for all dog lovers by uploading your canine pet’s medical records as well. How to get involved as a veterinarian: · If you are a veterinarian and interested in having your clinic/practice opt into the Take C.H.A.R.G.E. Registry, please visit TakeChargeRegistry.com to fill out the Veterinarian Practice Registration form. · All research and academia related activities will be de-identified and anonymized to ensure 100% participant and veterinary information protection. · Once you opt in, the Take C.H.A.R.G.E. Registry will have access to all of your current and newly diagnosed canine patients with cancer. These files will be automatically uploaded into the Take C.H.A.R.G.E. Registry in real time, so no further action is needed once you opt in. How to get involved as a dog owner: · If you are a pet owner and have a PDF of your dog's medical records, simply upload them into the Registry by visiting TakeChargeRegistry.com. · If you do not have your dog's medical records, tell your veterinarian about the Registry at your next visit and encourage them to join! · Follow us on our social channels and reshare with your friends! @Take C.H.A.R.G.E. @takechargereg @takechargeregistry --------------------------- About Susan Ettinger Dr. Sue Ettinger is a practicing veterinary cancer specialist, international speaker, book author, and vlogger (video blogger). She is one of approximately 450 board-certified specialists in medical oncology in North America and currently practices at Veterinary Referral and Emergency Center in Norwalk, Connecticut. She is co-founder and Chief Medical Officer of Fidu, a teleconsulting company to bring together general practice veterinarians and boarded veterinary specialists. She received her veterinary training at Cornell University College of Veterinary Medicine. She completed her residency in medical oncology at the Animal Medical Center in NYC in 2003. She was voted the 2019 Western Veterinary Conference (WVC) Small Animal Continuing Educator of the Year and has recently received awards for Exceptional Doctor Performance and the Public Relations Achievement. Also known as Dr Sue Cancer Vet®, Dr. Sue is the co-author of the Second Edition of The Dog Cancer Survival Guide, which is a best-selling book in small animal health for the last several years. She is a frequent contributor to many veterinary publications, including Today’s Veterinary Practice, Today’s Veterinary Business, Clinician’s Brief, Veterinary Team Brief, & DVM360. She also has co-hosted the podcast The Pet Cancer Vet and is a frequent guest on many veterinary podcasts. There are many myths and misconceptions about cancer in dogs and cats. Most cancers are treatable, and there are a variety of treatment options. Dr Sue’s focus is to provide comprehensive and compassionate care. She strives to minimize side effects – from the cancer itself and treatment – to help her patients lead active, normal lives even while undergoing treatment. Her motto is live longer, live well. Dr. Sue is most passionate about raising cancer awareness, and she has developed “ See Something, Do Something, Why Wait? Aspirate.® ” to promote early cancer detection and diagnosis. This cancer awareness initiative for skin and superficial tumors in dogs and cats provides a set of guidelines for pet owners and veterinarians to help identify the best management for skin and subcutaneous (under the skin) masses in dogs and cats. Masses must be sampled and evaluated under a microscope to determine what they are. The sooner we determine whether a mass is cancerous and should be removed, the better for our pets. Most skin and subcutaneous tumors can be cured with surgery alone if diagnosed early when masses are small. Early detection saves lives. Lisa Conte, Jaguar Health Founder & CEO Lisa Conte is the founder, president and chief executive officer, and a member of the board of directors of Jaguar Health, a commercial-stage pharmaceuticals company committed to discovering, developing and commercializing plant-based prescription medicines for urgent global health needs. Mytesi®, the company’s FDA-approved drug product, is a first-in-class, plant-based anti-secretory agent and the first oral drug approved under FDA Botanical Guidance. In 1989, Ms. Conte also founded Shaman Pharmaceuticals, Inc. and has pioneered plant-based prescription medicine investigation and development for more than 30 years, including a recent Entheogen Therapeutics Initiative looking at psychoactive plants for novel cures for mental health disorders; and Napo Therapeutics, S.p.A., a company established in Italy with a focus on the treatment of rare diseases from plant-based prescription medicines under license from Jaguar Health. Ms. Conte is currently a member of the board of directors of the Healing Forest Conservatory and Napo Therapeutics, and serves on the Editorial Advisory Board of Life Science Leader magazine. She holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College, and is also the parent of two Jack Russell Terriers and a Belgium Warmblood. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 21, 2022 05:00 PM Eastern Daylight Time

Video

NextFerm Technologies Announces First Commercial Production of ProteVin™, Its Vegan Protein

NextFerm Technologies Ltd.

This marks the achievement of first out of five strategic milestones set by the company for 2022 The Company expects to supply first orders of ProteVin™ in the coming weeks; Company is currently in dialogues with food and dietary supplement global companies for the integration of ProteVin™ in their alternative product lines NextFerm Technologies Ltd. (TASE:NXFR), a food-tech company developing ProteVin™, a vegan, yeast-based, non-GMO protein alternative and other innovative yeast-based nutrients, today announced the end of commissioning period of the commercial facility in Canada and first commercial production of ProteVin™, Its Vegan Protein. The operation of first commercial facility following commissioning and successful production of first batches mark the achievement of the first milestone out of five milestones set by the company for 2022. The Company continues to progress towards achieving the rest of its objectives for 2022, including delivery of initial orders received, increasing market demand for ProteVin™, receipt of additional purchase orders and expanding penetration into the global food market. In parallel, increasing commercial production capacity to an industrial scale of hundreds of tons per year in 2023. Boaz Noy, Chief Executive Officer of NextFerm, said: "Initiating commercial production of Protevin™, marks a significant milestone for the company moving forward from R&D phase to commercial phase. Achieving this milestone allows us to progress towards achieving the additional milestones we set for 2022. In the coming weeks, we expect to supply first orders of ProteVin™ for customers in the field of sports nutrition formulas." "The alternative protein market is the main growth engine of the global food industry, and we expect high demands for Protevin™, as a proprietary vegan protein source for a variety of alternative food products, with a rich amino acid composition similar to animal-based protein, highest digestibility factor (PDCAST=1) and neutral flavor." About NextFerm Technologies NextFerm Technologies, traded on the Tel Aviv Stock Exchange (TASE: NXFR) is a food-tech company engaged in the research, development, manufacturing and marketing of innovative, functional and vegan yeast-derived, non-GMO protein alternatives for various applications in the food and food supplement markets and the growing market for animal-derived protein alternatives. NextFerm's flagship product is ProteVin™, a vegan, yeast-derived protein alternative with nutritional value that is similar to animal-derived protein (Amino acid profile BCAA=21%, Leucine=9%, EAA=53% and high digestibility PDCAAS=1) and a neutral flavor, with no aftertastes that are typical of plant-based protein. ProteVin™ is designed for a variety of categories in the alternative protein market, which is estimated at USD 20 billion in terms of final products and at USD 5 billion in terms of raw materials with an annual growth rate of above 20%, including milk and dairy substitutes, meat substitutes and additional categories such as infant nutrition, adult nutrition, and sports nutrition. NextFerm has just commercialized the product as reported. Another product currently being sold is Astaferm®, an innovative astaxanthin-based antioxidant derived from yeast that has been sold in the US since the end of 2020 through well-established and leading brands in the food supplement market in the US. In July 2021, the Company received Regulatory marketing approval in Canada. The company has additional products which have been licensed to Lallemand, a global giant focused on yeast. For more information, visit the NextFerm website at: www.nextferm.com Legal Notice Regarding Forward-Looking Statements This announcement also includes forecasts, projections, assessments, estimates and other information which refer to future events and matters, the realization of which is uncertain and not exclusively under the Company’s control (forward-looking information). The main facts and data used to support this information are facts and data regarding the current position of the Company and its businesses (including the scope of sales and levels of profitability, manpower, commercial engagements and more), facts and data regarding the current global position of the Company’s operating segments (including industry-specific financial developments, environmental regulatory developments, the competitive environment, technological developments, the reinsurance market and more), and macro-economic facts and data (including the economic situation both in Israel and around the world, yields in the capital markets, social and state developments and more), all as known by the Company when publishing this announcement. The forward-looking information included above in this announcement is significantly based upon, in addition to the existing information held by the Company, on the Company’s current assessments and expectations of future developments vis-a-vis each one of the aforementioned parameters, and the interconnectedness of each one of these developments. The Company has no certainty that its forecasts and assessments will indeed eventuate, and the Company’s operating results may be materially different than the results assessed or implicit based on that set forth above, inter alia, as a result of a change in any of the aforementioned factors. Contact Details Investor and Media Contact Meirav Gomeh-Bauer +972 54-476-4979 meirav@bauerg.com Company Website https://www.nextferm.com/

June 20, 2022 10:05 AM Eastern Daylight Time

UK MEDTECH COMPANY TO HELP PROTECT US HEALTHCARE WORKERS AND US CITIZENS FROM 1 MILLON NEEDLESTICK INJURIES EACH YEAR

NeedleSmart

SAFETY INITIATIVE AND COMPLIANCE WILL SAVE AMERICAN HEALTHCARE INDUSTRY $1 BILLION British smart MedTech company NeedleSmart, which is pioneering disruptive technologies in the global healthcare sector, is expanding into the US healthcare market to protect American healthcare workers and patients from the rising tide of needlestick injuries (NSI). In the US alone, more than 1 Million NSI are reported each year, affecting frontline nurses, healthcare workers and patients. However, it is estimated that the more accurate figure may be five times that number, due to a culture of underreporting. Initially NeedleSmart will focus their efforts on helping the US healthcare system reduce Needlestick injuries (NSI). Pre Covid-19, NSI cost the US healthcare industry more than $1Bn each year. A cost built on treatments (both physical and mental), absenteeism, agency staff and in many cases law suits. Approximately 5.6 million healthcare workers in the US are at risk of occupational exposure to bloodborne pathogens via NSI or other sharps-related injuries, according to the Occupational Safety and Health Administration every year. Needlestick injuries are caused when a hypodermic needle accidentally punctures the skin. These injuries – which can happen at any time, however the NSI which carry the most significant risks are those that happen after exposure to the patient. The Centre for Disease Control and Prevention (CDC) estimates that at least 385,000 NSI occur each year to hospital-based healthcare workers, amounting to more than 1,000 NSI per day amongst hospital healthcare staff. Many more of those NSI also occur through emergency services, homecare and nursing homes. The CDC has also targeted the elimination of NSI as an agency priority, with both federal and state laws increasing enforcement of NSI injury prevention. Over 41% of NSI occur during use, with 41% occurring after use and before disposal, 15% occurring during and after disposal and 4% in other settings. NeedleSmart is working closely with lawmakers and Government agencies in the US to inform, advance and extend legislation that will protect healthcare workers and frontline staff. US based NeedleSmart Chief Operating Officer Michael Barron said: “Needlestick injuries were already a serious global problem pre Covid-19, with more than 3 million reported cases each year and rising. The introduction of a global vaccination program has added significantly to this with pandemic with NSI statistics yet to be made publicly available. The global supply and use of needles is at an all-time record, which means the risk of becoming injured by a NSI has also greatly increased. If we factor into this equation that hospitals, emergency services and healthcare staff are under even more pressure, facing longer shifts and suffering from burnout and chronic fatigue, this creates the perfect storm for an unprecedented increase and risk of NSI to US healthcare and frontline emergency services staff. While the reported figure of NSI in the US is 1 Million, it is believed that the actual figure could be considerably more due to a culture of under reporting NSI. With NeedleSmart, we can not only reduce and prevent NSI to key frontline healthcare staff, EMS personnel and patients, but we can increase staff efficiencies as we link our bespoke software solutions directly to the NeedleSmart Pro hardware and eliminate significant amounts of pre and post procedure administration and in-efficiency. Our audit and compliance software runs alongside the safe destruction technology to create a singular end to end workflow. NeedleSmart will significantly reduce post procedural PPNSI, directly targeting and reducing the $1Bn per year associated costs.” NeedleSmart, which has offices in Liverpool, England and Philadelphia USA, is already at the forefront of pioneering disruptive technologies with the British National Health Service (NHS) to prevent NSI to NHS healthcare workers and clinicians. It is also developing carbon reduction strategies in clinical waste disposal, as well as digitising vaccination programmes NeedleSmart has achieved FDA approval as a Class II medical device, making it the first UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD)). The NeedleSmart Pro device destroys a contaminated hypodermic needle in a sealed chamber in just 6 seconds, minimizing post-procedural NSI. The device heats the needle to 2372 degrees Fahrenheit, killing potentially harmful pathogens, viruses and bacteria adhering to the needle. Within seconds, the needle is compressed into a tiny ball and released from the NeedleSmart device as a safe sphere of metal at the tip of the syringe. The product can be seen here https://youtu.be/C968RkWtSi8 Aligned with this Needle Smart have set the ambitious goal of re-purposing this waste away from plastic sharps containers to a 96% recycled cardboard clinical waste container in the near future. NeedleSmart has developed a ground-breaking set of disruptive technologies in digital data and AI for medical and clinical records, healthcare worker safety and carbon reduction programs in clinical waste. To learn more about how the Needle Smart Pro works with the DVS system can be seen here https://www.youtube.com/watch?v=nIAzsMwyBDc NeedleSmart’s disruptive smart MedTech technologies are focussed on: Safety: The reduction and hopeful elimination of harmful post procedural NSI to US healthcare workers and patients Sustainability: Reducing the associated carbon footprint by up to 95% Efficiency: The digitalization of vaccination programs, medical treatments, clinical workflows and associated records. Cliff Kirby, NeedleSmart’s Global CEO, added “Not only is this the world’s first safe needle destruction technology that also has FDA 510 (k) approval as a Class II medical device (Sharps Needle Destruction Device (NDD)), but it is the only Smart MedTech to have a unique compliance and audit software each time a needle is used. “When used as part of a vaccination program, our system offers 30-50% increased efficiencies, providing unique compliance with a digital audit trail from the point of when the needle is unwrapped from its sterile packaging. This provides a full audit trail and compliance including, vaccination batch and manufacturer, the healthcare professional administering the vaccination, date, time and patient details – right through to the safe destruction of the needle. This firmly puts healthcare and EMS worker safety at the forefront.” ENDS For more information on Needle Smart, visit www.needlesmart.com www.digitalvaccination.com The Needle Smart process explainer https://youtu.be/C968RkWtSi8 The Needle Smart DVS explainer https://www.youtube.com/watch?v=nIAzsMwyBDc ABOUT NEEDLESMART NeedleSmart is a market-leading, British-patented needle destruction technology engineered in the UK, with offices in Knowsley and Pittsburgh, Pennsylvania. Its award-winning NeedleSmart Pro needle destruction device has achieved FDA approval as a Class II medical device, being the first UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD)). As well as contributing to the reduction of needlestick injuries and their consequential costs, the NeedleSmart process has the potential to reduce the cost and increase efficiency of used needle disposal. NeedleSmart’s innovative technology also offers the opportunity to move hypodermic needles, syringes and consumables associated with the injection/vaccination process, away from conventional sharps bins to a solution that allows recycling to become a possibility. NeedleSmart technology compresses the needle, significantly reducing the needle footprint leading to a minimum of 50% increase in needle count per sharps bin. After the unexpected Covid-19 pandemic and the mass vaccination program that followed, NeedleSmart's Digital Vaccination System (DVS) was created to support mass vaccination program, digitalizing the vaccination process, with every detail being automatically recorded in the cloud. DVS delivers a single solution that can coordinate every individual vaccination initiative into a single, coherent vaccination program. ABOUT MICHAEL BARRON CHIEF OPERATING OFFICER NEEDLESMART US Michael Barron has spent the last 30 years helping to build, scale, and lead high growth companies. As both an investor and executive, he has helped take several firms from inception to over $1Bn in assets. Michael has been featured in The Wall Street Journal and Investor’s Business Daily. He has been a regular guest on Bloomberg and CNBC. He is a board member at The Foreign Policy Research Institute and The Satell Institute. He a graduate of Villanova University. For more information https://www.linkedin.com/in/michaelbarron100/ MEDIA NOTICE NeedleSmart assets and images can be downloaded here https://we.tl/t-NQfuq4O9tr Contact Details NeedleSmart Gerard Franklin +44 7791 039636 gerard@i5media.co.uk Company Website https://www.needlesmart.com/

June 20, 2022 12:30 AM Eastern Daylight Time

Modern Weight Loss: What is Personalized Weight Care and Why You Should Try It

YourUpdateTV

According to the CDC, overweight and obesity are risk factors for many serious diseases and health conditions, including heart disease, stroke, type 2 diabetes, and some cancers, all of which are among the leading causes of preventable death. Recently Dr. Rekha Kumar from Found conducted a satellite media tour to talk about personalized weight loss and its benefits. A video accompanying this announcement is available at: https://youtu.be/ZEx5tcYjrlQ It is time we push back against harmful and outdated weight loss culture and start thinking about our overall health and weight care. A poll of 2,000 adults conducted by weight care platform, Found, revealed that 91% have tried at least one strategy for weight loss, with half revealing that they’ve tried 11 different methods of weight loss. According to that same poll: ● 25% of people even confessed to doing up to 16 diets in their lifetime! ● But only 15% described their weight loss experience as “rewarding” ● Respondents felt that losing weight required more sacrifice than having kids ( 33% )! ● 9 in 10 Americans have tried at least one weight loss strategy ● 33% wished they had access to prescription weight loss medications ● Almost four in five (79%) want to be healthier, not skinnier. Found is an evidence-based weight care solution that combines the best of modern medicine with personalized coaching and community. Centered around clinical care and lasting behavior change, Found provides its members with a comprehensive weight loss program that delivers long term, sustainable results. Found designs personalized treatments around every factor that makes people unique — from biology, medical history, mental health, existent lifestyle, goals, and more. Found’s members are supported by the best of consumer technology, and a team that includes doctors to prescribe safe medication, and coaches to guide them on nutrition, movement, sleep, and emotional health. They call this weight care. When diet and exercise don’t lead to effective weight loss, sometimes it’s our biology that’s holding us back. Much of how your body loses, gains, and maintains weight is predetermined by your biology. This means no amount of working out, eating healthy, or sheer willpower can sustain weight loss if your biology’s not set up for it. Medication can, which is why Found offers more medication options than any other program. Online weight loss means Found took the doctor's office out of the equation. The telehealth platform provides one-on-one medical, nutritional, and movement guidance from their experts, through an app that can be accessed anywhere and at any time. Found’s proprietary weight care platform is available via the App Store, Google Play, as well as on joinfound.com Rekha Kumar bio: Dr. Rekha Kumar is recognized as an international leader in the field of Obesity Medicine. She is Chief Medical Officer at weight care platform Found, as well as a practicing endocrinologist at an academic medical center in New York City. She also served as the former medical director of the American Board of Obesity Medicine. Dr. Kumar has lectured internationally on the topic of the medical assessment and treatment of obesity. She has published several papers and textbook chapters in her field and serves as an Associate Editor of the journal Obesity. She is frequently quoted in the media on topics ranging from the diabetes epidemic in the United States to discussing fad diets, exercise trends, and the complications of Covid-19 in patients with obesity. Dr. Kumar’s areas of expertise include the clinical assessment of patients obesity and metabolic syndrome, the effect of obesity on reproductive health and fertility, as well as thyroid disease. Dr. Kumar completed her undergraduate studies at Duke University then received her master’s degree in Physiology from Georgetown University. She continued on to receive her M.D. from New York Medical College and completed her residency training in Internal Medicine at the New York Presbyterian Hospital/Weill-Cornell Medical College. Dr. Kumar obtained her clinical fellowship in the combined Diabetes, Endocrinology, and Metabolism program at the Weill-Cornell Medical College/New York Presbyterian Hospital and the Memorial Sloan Kettering Cancer Center. Dr. Kumar has traveled abroad to India, China, and Tanzania to understand the scope of metabolic disease globally. She serves on the board of advisors of the Duke Global Health Institute. Dr. Kumar is Board Certified in Internal Medicine, Endocrinology, Diabetes, & Metabolism, and Obesity Medicine. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 17, 2022 10:00 AM Eastern Daylight Time

Video

2022 GUIDE TO SUMMERTIME FUN

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/eB9T1JYMnNI The hot and long days of summer are upon us and families from coast to coast are eager for some fun in the sun. In fact, more Americans plan to travel this year, with 73% of consumers expected to take an average of two trips. Hitting the road remains popular, while confidence in flying has increased from last year. According to recent stats, 79% of people plan to drive to at least one vacation destination, while air travel accounts for 45%—increasing by 5% compared to 2021. However, staycations remain popular due to record-high gas prices, escalating airfares and the war in Ukraine. It’s been found that 25% of Americans will travel shorter distances and 23% plan on less expensive activities. Whether traveling near or far, spending time with family and friends ranks high on the list of anticipated summer activities, including beaches, ball games and barbeques. Grilling season has always been a favorite with many backyard chefs expected to cook up and serve 50 billion hamburgers and 20 billion hotdogs this year. Wellness is also a high-priority, with many Americans engaging in healthful summertime habits, like running, biking, and including supplements into their diets. Braun-Silva has some unique ways to enjoy the summer while building special memories with friends and family. TRAVEL SMART: Summer travel is here and it is going to be a busy season. New Amex Trendex data found that more than half of respondents agree they plan to travel more this summer than in previous years. Braun-Silva’s first tip is to travel smart, saying, “Most of us are looking for added flexibility and confidence when booking a trip. Whether visiting white sandy beaches along crystal blue waters or hiking a national park, there are services available to help make traveling easy and convenient." One way to travel smart is through American Express' Trip Cancel Guard, a new benefit for American Express U.S. Card Members that truly allows travelers to cancel flights for any reason. The smart travel tips don't stop there - from building a dream itinerary to finding the best offers on flights and hotels, consider booking your travel with American Express to up the ante. American Express Travel is a one-stop-shop for planning a vacation thanks to their world-class customer service, 24/7 access to expert travel consultants, exclusive programs and benefits, and more. For those who want an elevated travel experience without breaking the bank, Braun-Silva says U.S. Platinum Card Members can get access to the International Airline Program through Amex Travel which gives travelers savings on international flights for First, Business and Premium Economy seats across more than 20 world class airlines. For more information, visit AmexTravel.com to book. Terms apply. Direct link: AmexTravel.com Social media handles: @AmericanExpress Hashtags: #AmexTravel PRIORITIZE WELLNESS: Overall wellness is a high-priority for many of us. Braun-Silva points out that there are many ways we can engage in healthful summertime habits. “This time of year is perfect for walking, hiking, running, and biking. To support these outdoor activities, it’s helpful to include supplements into our diets,” says Braun-Silva, “As we age our bodies produce less collagen, which helps with healthy joints and skin elasticity. I’ve been adding collagen into my daily routine for years.” MD Logic Health’s Marine Collagen with COFACTORS is made from the highest quality wild-caught non-GMO white fish, which promotes lean muscle mass, strong bones, hair, skin, and nails, supports gut health, and promotes new Collagen production. Braun-Silva adds, “It easily dissolves and has no fishy taste or smell so you can add it to fun summertime drinks, like smoothies, and your meals, to boost your protein intake, at any time without the unnecessary calories.” MD Logic Health, Marine Collagen has a special blend of cofactors including Vitamins A, C, Zinc, and Copper, and also includes Biotin, so that your health can radiate from the inside out. For a limited time, use code COLLAGEN for 15% off. For more information, go https://www.mdlogichealth.com/products/marine-collagen. Direct link: https://www.mdlogichealth.com/products/marine-collagen Social media handles: @mdlogichealth Hashtags: #mdlogichealth #supplementinglife KEEP IT COOL: As the temperatures heat up, Braun-Silva says look out for ways to make summer a bit cooler, adding, “This is one of my favorite tips and it’s really a no brainer—ice cream!” According to a new national poll, 34% of respondents say eating ice cream in summer makes them feel like a kid again. The lifestyles expert says, “One of my favorite summer desserts is a delicious ice cream cake—perfect for pool parties, backyard BBQs, Father’s Day, or any fun summer gathering. Everyone loves them.” There are several cakes to choose from, like Carvel Sheet Cake and Lil Love Strawberry Crunchie Cake to OREO. Braun-Silva recommends picking one or two up at your local grocery store by looking in the bakery freezer case or by going to ILoveIceCreamCakes.com for a store locator. For more information, visit ILoveIceCreamCakes.com for a store locator. Direct link: ILoveIceCreamCakes.com Social media handles: @ILoveIceCreamCakes Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 16, 2022 11:00 AM Eastern Daylight Time

Video

Modivcare Honored as Stevie Award Winner In 2022 American Business Awards®

Modivcare

Modivcare Inc. (“Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions, has been named the winner of a Stevie® Award in The 20 th Annual American Business Awards®. Modivcare won in the highly competitive category of Community Relations PR Campaign of the Year for its collaboration with Access Gallery, a Denver-based non-profit organization that provides empowerment and economic opportunities for artists with disabilities, including the ability to earn money from their art. Access Gallery artists designed pieces that embody Modivcare’s values, vision, and purpose: to connect people to care by eliminating barriers to transportation, personal care, remote patient monitoring, and meals. The Modivcare communications and marketing team, the Access Gallery marketing team, and Modivcare's external PR agency, Amendola Communications, collaborated on a campaign that would focus on the March 2022 installation of the “Connecting Communities to Care” collection in Modivcare’s new Denver headquarters. Key elements of the campaign employed media relations, social media, and internal communications tactics to secure television and print coverage, as well as leveraged social media and internal communications to increase overall exposure. As a result of these tactics, local Denver Fox affiliate KDFR, shared a story on March 16 about the Access Gallery and Modivcare collaboration. In addition, the team published multiple posts on LinkedIn, with each post performing exceptionally and significantly above the industry average. Along with helping raise awareness of Access Gallery, Modivcare’s joint project with the Denver non-profit: Funded more than $150,000 in economic opportunity for local artists with disabilities Involved more than 25 artists with disabilities Offered a creative outlet for artists to express themselves, earn money, and showcase their skills Will result in more than 100 unique pieces of custom art developed by July 2022 “Our company is honored to receive a Stevie® Award from the Annual American Business Awards®,” said Dan Greenleaf, President and Chief Executive Officer of Modivcare. “Access Gallery is a fantastic organization that provides opportunities to incredibly talented people. We’re proud to have helped raise Access Gallery’s profile by displaying its unique art in our building and offering economic empowerment to its artists. The art serves as a visual reminder of our purpose of Making Connections to Care for the underserved and inspires us every day.” “‘Connecting Communities to Care’ is the perfect name for this collection,” said Damon McLeese, Executive Director of Access Gallery. “Modivcare connects the underserved to quality care and now they are connecting the same group to economic opportunities by filling their corporate office space with their artwork.” Winners were determined by the average scores of more than 230 professionals worldwide in a three-month judging process with more than 3,700 nominations from organizations of all sizes and in virtually every industry. Nicknamed the Stevies for the Greek word meaning “crowned,” the awards were presented to winners at a gala ceremony at the Marriott Marquis Hotel in New York on Monday, June 13. The American Business Awards® list of 2022 Stevie winners are available at www.StevieAwards.com/ABA. About Modivcare Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal care and remote patient monitoring. To learn more about Modivcare, please visit www.modivcare.com. About the Stevie Awards Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com. Contact Details Kate Zerone Director, Ombudsman & Communications kate.zerone@modivcare.com Marcia Rhodes Amendola Communications mrhodes@acmarketingpr.com

June 16, 2022 09:30 AM Eastern Daylight Time

Image

1 ... 219 220 221 222 223 ... 306